Compounded Sema Injectable denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied Compounded Semaglutide as Non-Formulary — and Why You Can Appeal

UnitedHealthcare's formulary (drug list) determines which medications the plan covers at standard cost-sharing. Compounded semaglutide injectable is not an FDA-approved drug product and therefore does not appear on most insurers' standard formularies as a covered item. When your pharmacy submits a claim for a compounded preparation, UHC's system rejects it as non-formulary — meaning there is no coverage tier assigned, not necessarily that the drug is medically inappropriate.

The appropriate appeal pathway is a formulary exception (also called a medical exception or non-formulary exception request). These are granted regularly when the prescriber can document that no formulary alternative is clinically appropriate for this patient.

## Your Federal Appeal Rights

Under ACA §2719 you may pursue independent external review after exhausting UHC's internal process. Under ERISA §503 (employer plans) you are entitled to a full-and-fair review. The external-review window is generally open for approximately four months after a final internal denial. For urgent medical situations, request an expedited review — UHC must respond within 72 hours.

## The Concrete Appeal Process

1. Ask your prescriber to submit a formulary exception request to UHC simultaneously with or immediately after the initial denial. 2. If the exception is denied, file a Level 1 internal appeal with a full clinical package. 3. Escalate to external IRO review if the internal process does not resolve in your favor.

## Documentation to Gather

• Diagnosis confirmation — chart notes, diagnostic codes, and clinical assessments for the underlying condition.
• Formulary alternatives tried or contraindicated — the cornerstone of a formulary exception is showing that each formulary option in the same therapeutic class was tried and failed, caused unacceptable adverse effects, or is contraindicated for this patient. Provide dated records for each.
• Clinical severity — documentation showing why effective treatment cannot be delayed and why a formulary alternative is not a viable substitute.
• Prescriber medical-necessity letter — should identify the formulary alternatives, explain specifically why each is inappropriate for this patient (not just a general preference for the compounded form), and state why the compounded preparation is medically necessary.
• Prescribing label and compounding pharmacy documentation — attach documentation showing the compounded formulation is being prepared to a defined standard and is intended to deliver the same active ingredient as the referenced branded product.

## Criteria-Mapping Structure

Request UHC's formulary-exception criteria in writing. Then address each element:

| UHC Formulary-Exception Criterion | Supporting Evidence | |---|---| | [Copy each criterion from UHC's exception policy verbatim] | [Chart date, note, trial record, or prescriber statement satisfying the criterion] |

The single most important element in a formulary-exception appeal is a systematic, drug-by-drug explanation of why each formulary alternative failed or cannot be used. A prescriber letter that addresses alternatives generically is far less effective than one that names each alternative and explains the specific clinical reason it is not appropriate for this patient.